These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

140 related articles for article (PubMed ID: 3315579)

  • 21. Intracoronary streptokinase versus intravenous anisoylated plasminogen streptokinase activator complex in the treatment of acute myocardial infarction.
    Kaspar L; Karnik R; Sehnal E; Zajicek P; Ziegler B; Slany J
    Drugs; 1987; 33 Suppl 3():179-82. PubMed ID: 3315588
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Summary of early clinical experience with anisoylated plasminogen streptokinase activator complex in the treatment of acute myocardial infarction.
    Jackson D
    Drugs; 1987; 33 Suppl 3():104-11. PubMed ID: 3315574
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Safety and tolerance data from the Belgian multicentre study of anisoylated plasminogen streptokinase activator complex versus heparin in acute myocardial infarction.
    Bossaert LL
    Drugs; 1987; 33 Suppl 3():287-92. PubMed ID: 3315610
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Safety and side effects of anisoylated plasminogen streptokinase activator complex and streptokinase in patients with acute myocardial infarction. Interim report of the IRS II Study.
    Monassier JP; Hanssen M
    Drugs; 1987; 33 Suppl 3():282-5. PubMed ID: 3315608
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Development and evaluation of anisoylated plasminogen streptokinase activator complex (APSAC) as a second generation thrombolytic agent.
    Anderson JL
    J Am Coll Cardiol; 1987 Nov; 10(5 Suppl B):22B-27B. PubMed ID: 3312369
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A double-blind randomised dose-effect trial of anisoylated plasminogen streptokinase activator complex (APSAC) in acute myocardial infarction. The APSAC Research Group.
    Clin Trials Metaanal; 1993 Nov; 28(6):317-28. PubMed ID: 10150180
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Comparison of the safety and tolerance of intravenous anisoylated plasminogen streptokinase activator complex and intracoronary streptokinase in acute myocardial infarction.
    de Swart JB
    Drugs; 1987; 33 Suppl 3():279-81. PubMed ID: 3315607
    [No Abstract]   [Full Text] [Related]  

  • 28. Anisoylated plasminogen streptokinase activator complex versus streptokinase in acute myocardial infarction. Preliminary results of a randomised study.
    Monnier P; Sigwart U; Vincent A; Bachmann F; Goy JJ; Schaller MD; Kaufmann U; Badan M; Grbic M; Perret C
    Drugs; 1987; 33 Suppl 3():175-8. PubMed ID: 3315587
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Fibrinogen concentration and coronary artery reperfusion after intravenous anisoylated plasminogen streptokinase activator complex or intracoronary streptokinase therapy.
    Marder VJ; Kinsella PA; Brown MJ
    Drugs; 1987; 33 Suppl 3():237-41. PubMed ID: 3315601
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Multicenter trial of intravenous anisoylated plasminogen streptokinase activator complex (APSAC) in acute myocardial infarction: effects on infarct size and left ventricular function.
    Bassand JP; Machecourt J; Cassagnes J; Anguenot T; Lusson R; Borel E; Peycelon P; Wolf E; Ducellier D
    J Am Coll Cardiol; 1989 Apr; 13(5):988-97. PubMed ID: 2647817
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Acute coronary occlusion and reperfusion. Reliability of angiographic classification and grading.
    Sorensen SG; Hackworthy RA; Fitzpatrick PG; Barry WH; Menlove RL; Anderson JL
    Drugs; 1987; 33 Suppl 3():163-8. PubMed ID: 3315585
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Preliminary safety and tolerance data obtained in the comparative study of anisoylated plasminogen streptokinase activator complex versus heparin.
    Croydon EA
    Drugs; 1987; 33 Suppl 3():293-6. PubMed ID: 3315611
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Assessment of left ventricular function in a randomised study of intravenous anisoylated plasminogen streptokinase activator complex versus heparin in acute myocardial infarction. Preliminary results of the European Multicentre Study (Belgian Centres).
    Taeymans Y; Materne P
    Drugs; 1987; 33 Suppl 3():216-20. PubMed ID: 3315594
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Prehospital use of APSAC: results of a placebo-controlled study.
    Castaigne AD; Hervé C; Duval-Moulin AM; Gaillard M; Dubois-Rande JL; Boesch C; Wolf M; Lellouche D; Jan F; Vernant P
    Am J Cardiol; 1989 Jul; 64(2):30A-33A; discussion 41A-42A. PubMed ID: 2662741
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Analysis of coagulation and fibrinolysis after intravenous anisoylated plasminogen streptokinase activator complex or heparin in patients with acute myocardial infarction. A Belgian multicentre study.
    Renkin J; Beys CC; Lavenne-Pardonge E; Pintens H; Col J
    Drugs; 1987; 33 Suppl 3():253-60. PubMed ID: 3315603
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Comparative tolerance and complications in a multicentre trial of intracoronary streptokinase and intravenous anisoylated plasminogen streptokinase activator complex in acute myocardial infarction.
    Rothbard RL
    Drugs; 1987; 33 Suppl 3():276-8. PubMed ID: 3315606
    [TBL] [Abstract][Full Text] [Related]  

  • 37. AIMS. The design and conduct of a multicentre mortality study comparing placebo and anisoylated plasminogen streptokinase activator complex 30 units intravenously for the treatment of acute myocardial infarction of less than 6 hours duration. UK APSAC Advisory Committee.
    Drugs; 1987; 33 Suppl 3():227-8. PubMed ID: 3315598
    [No Abstract]   [Full Text] [Related]  

  • 38. [A european multicenter and randomized study of APSAC versus streptokinase in myocardial infarction].
    Charbonnier B; Cribier A; Monassier JP; Favier JP; Materne P; Brochier ML; Letac B; Hanssen M; Sacrez A; Kulbertus H
    Arch Mal Coeur Vaiss; 1989 Sep; 82(9):1565-71. PubMed ID: 2510677
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Anisoylated plasminogen streptokinase complex during the acute phase of myocardial infarction. Results of a multicenter double-blind study versus heparin].
    Cassagnes J; Bassand JP; Machecourt J; Lusson JR; Anguenot T; Borel E; Vacher D; Denis B; Maurat JP; Jallut H
    Arch Mal Coeur Vaiss; 1990 Apr; 83(4):453-60. PubMed ID: 2111665
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Biological study of intravenous anisoylated plasminogen streptokinase activator complex in acute myocardial infarction.
    Samama M; Conard J; Verdy E; van Dreden P; Nguyen G; Combrisson A; Acar J
    Drugs; 1987; 33 Suppl 3():268-74. PubMed ID: 3315605
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.